Publicacións en colaboración con investigadores/as de Universidad Autónoma de Madrid (9)

2024

  1. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1647-1663

2023

  1. Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2679-2691), 10.1007/s12094-023-03216-3)

    Clinical and Translational Oncology

  2. SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2679-2691

2021

  1. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. Lung cancer symptoms at diagnosis: Results of a nationwide registry study

    ESMO Open, Vol. 5, Núm. 6

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

2011

  1. Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations

    Clinical Cancer Research, Vol. 17, Núm. 5, pp. 1160-1168

2010

  1. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

    Journal of Translational Medicine, Vol. 8

2009

  1. Screening for epidermal growth factor receptor mutations in lung cancer

    New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967